DOTA-Tyr(3)- 90Y-octreotide

used in peptide receptor-targeted radionuclide therapy; also known as DOTATOC, but this also has been used for version with Phe at position 1

Also Known As:

90Y-octreotide, DOTA-Tyr(3)-; ((90)yttrium-DOTA)-TOC; (90Y-DOTA(0),Tyr(3))octreotide; (90Y-DTPA(0), Tyr(3))octreotide; 90Y-DOTA-3-Tyr-octreotide; 90Y-DOTATOC; 90Y-octreotide, DTPA(0)-Tyr(3)-; 90Y-octreotide, DTPA(0)-tyrosyl(3)-; 90Y-octroetide, DOTA-tyrosyl(3)-; DOTATOC-90Y; OctreoTher; Y(III)-DOTATOC

Networked: 44 relevant articles (5 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Menda, Yusuf: 6 articles (01/2021 - 08/2003)
2.	Mueller-Brand, Jan: 5 articles (11/2015 - 03/2002)
3.	Cremonesi, Marta: 4 articles (06/2021 - 02/2004)
4.	O'Dorisio, M Sue: 4 articles (01/2021 - 04/2006)
5.	Forrer, Flavio: 4 articles (01/2019 - 08/2005)
6.	Maecke, Helmut R: 4 articles (01/2017 - 08/2005)
7.	O'Dorisio, Thomas: 4 articles (10/2010 - 08/2003)
8.	Mueller-Brand, J: 4 articles (01/2004 - 01/2000)
9.	Collamati, Francesco: 3 articles (06/2021 - 10/2015)
10.	Faccini, Riccardo: 3 articles (06/2021 - 10/2015)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2021 - "Conclusions: These first ex vivo RGS tests showed that this probe can discriminate very effectively between tumor and healthy tissues by the administration of low activities of 90Y-DOTATOC, allowing more precise surgery." 01/01/2021 - "In addition, the single treatment using 90Y-DOTATOC did not induce tumor shrinkage, indicating that more treatment cycles may be required. " 01/01/2018 - "A549WT and Panc-1WT tumors with SSTR2-expressing mMSCs treated with 90Y-DOTATOC showed significantly lower tumor volumes compared to controls (p < 0.05). " 07/01/2001 - "Tumor progression could not be stopped in any of the patients treated with 90Y-DOTATOC. " 12/01/1999 - "The aim of this work was to evaluate acute and late toxicity and the response rate in cancer patients administered 90Y-DOTATOC. "
2.	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/01/2006 - "90Y-DOTATOC is a safe and effective treatment for patients with metastatic neuroendocrine tumors." 06/01/2021 - "First Ex Vivo Results of β--Radioguided Surgery in Small Intestine Neuroendocrine Tumors with 90Y-DOTATOC." 01/01/2021 - "Methods: A phase 1 clinical trial was initiated for patients with nonoperable progressive neuroendocrine tumors using a combination of 90Y-DOTATOC plus 131I-MIBG. " 01/01/2000 - "Phase I clinical trials, conducted in patients with neuroendocrine tumors, established the safety and tolerability of the dose selected for further study and demonstrated the capacity of OctreoTher to deliver radiation doses to tumors that resulted in significant neuroendocrine tumor shrinkage. " 04/01/2006 - "Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model."
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2000 - "Novartis-sponsored phase II studies will soon begin to test the efficacy of OctreoTher in breast and small cell lung cancer. "
4.	Cushing Syndrome 03/01/2008 - "To the best of our knowledge, this is the first report of a multidisciplinary approach including peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE, which proved to be effective in improving clinical outcome in a case of metastatic endocrine carcinoma of the pancreas in conjunction with ectopic Cushing syndrome. " 03/01/2008 - "Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal."
5.	Carcinoma (Carcinomatosis) 03/01/2008 - "To the best of our knowledge, this is the first report of a multidisciplinary approach including peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE, which proved to be effective in improving clinical outcome in a case of metastatic endocrine carcinoma of the pancreas in conjunction with ectopic Cushing syndrome. "

Related Drugs and Biologics

1.	Somatostatin Receptors (Somatostatin Receptor)
2.	Radioisotopes (Radionuclides)
3.	Peptide Receptors (Peptide Receptor)
4.	Ga(III)-DOTATOC
5.	lutetium Lu 177 dotatate
6.	Biomarkers (Surrogate Marker)
7.	DOTA(0)-Tyr(3)- 177Lu-octreotide
8.	Coordination Complexes
9.	Sirtuins
10.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Radiotherapy
4.	Intravenous Administration
5.	Drug Therapy (Chemotherapy)